Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non‐Ho...
Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non‐Hodgkin's Lymphoma and Exposure–Response in CLL
About this item
Full title
Author / Creator
Gibiansky, E , Gibiansky, L , Carlile, D J , Jamois, C , Buchheit, V and Frey, N
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Treatment regimens involving obinutuzumab (GA101) demonstrated increased efficacy to rituximab in clinical trials for non‐Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). However, the pharmacokinetic (PK) properties and the exposure–response relationships of obinutuzumab still need to be fully described. Data from four clinical tria...
Alternative Titles
Full title
Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non‐Hodgkin's Lymphoma and Exposure–Response in CLL
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4474170
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4474170
Other Identifiers
ISSN
2163-8306
E-ISSN
2163-8306
DOI
10.1038/psp.2014.42
